Sponsor pipeline

TwoStep Therapeutics, Inc. clinical trial pipeline

Get alerts when TwoStep Therapeutics, Inc.'s trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-20

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.

  1. Notable

    (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy · Select Advanced Solid Tumors

    Recruitment opened

    Also in this update: Trial sites expanded: 0 → 3 locations; Start date changed from estimate of Oct 2026 to Sep 2, 2026

    TwoStep Therapeutics, Inc.Phase 1 NCT07814248 Registry history of NCT07814248 on ClinicalTrials.gov (opens the registry)

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1
1

Disease areas by active trials

Get alerts when TwoStep Therapeutics, Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free